

relugolix tablet (ORGOVYX)

Diagnoses Considered for Coverage:

- Advanced prostate cancer

Coverage Criteria:

For diagnosis of prostate cancer (PC):

- Being used as a single agent, **and**
 - One of the following:
 - Inadequate response to either injectable GnRH agonist [e.g. Zoladex (Goserelin), Lupron (leuprolide), Trelstar (triptorelin)] or GnRH antagonist [e.g. Firmagon (degarelix)], **or**
 - Intolerance or contraindication to both injectable GnRH agonist and antagonist not expected with Orgovyx,
- and**
- Dose does not exceed 360 mg loading dose orally on day 1, followed by 120 mg once daily.

Coverage Duration: one year

Effective Date: 6/28/2023